ARTICLE | Clinical News
Egilix TCell-DLI Cell Separation System regulatory update
October 1, 2001 7:00 AM UTC
BTRN received CE mark authorization for its Egilix TCell-DLI Cell Separation System for ex-vivo depletion of CD8+ T cells from donor leukocyte infusions used to augment the anti-tumor immune responses...